Literature DB >> 30184064

Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update.

Mônica R Gadelha1,2,3, Leandro Kasuki1,2,4, Dawn S T Lim5, Maria Fleseriu6,7,8.   

Abstract

Acromegaly is a chronic systemic disease with many complications and is associated with increased mortality when not adequately treated. Substantial advances in acromegaly treatment, as well as in the treatment of many of its complications, mainly diabetes mellitus, heart failure, and arterial hypertension, were achieved in the last decades. These developments allowed change in both prevalence and severity of some acromegaly complications and furthermore resulted in a reduction of mortality. Currently, mortality seems to be similar to the general population in adequately treated patients with acromegaly. In this review, we update the knowledge in complications of acromegaly and detail the effects of different acromegaly treatment options on these complications. Incidence of mortality, its correlation with GH (cumulative exposure vs last value), and IGF-I levels and the shift in the main cause of mortality in patients with acromegaly are also addressed.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30184064     DOI: 10.1210/er.2018-00115

Source DB:  PubMed          Journal:  Endocr Rev        ISSN: 0163-769X            Impact factor:   19.871


  61 in total

Review 1.  Electrophysiological features in acromegaly: re-thinking the arrhythmic risk?

Authors:  M Parolin; F Dassie; R Vettor; R P Steeds; P Maffei
Journal:  J Endocrinol Invest       Date:  2020-07-06       Impact factor: 4.256

Review 2.  Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly.

Authors:  Federico Gatto; Claudia Campana; Francesco Cocchiara; Giuliana Corica; Manuela Albertelli; Mara Boschetti; Gianluigi Zona; Diego Criminelli; Massimo Giusti; Diego Ferone
Journal:  Rev Endocr Metab Disord       Date:  2019-09       Impact factor: 6.514

3.  Exon 3-deleted growth hormone receptor isoform is not related to worse bone mineral density or microarchitecture or to increased fracture risk in acromegaly.

Authors:  J Pontes; M Madeira; C H A Lima; L L Ogino; F de Paula Paranhos Neto; L M C de Mendonça; M L F Farias; L Kasuki; M R Gadelha
Journal:  J Endocrinol Invest       Date:  2019-08-07       Impact factor: 4.256

4.  Physical exercise improves functional capacity and quality of life in patients with acromegaly: a 12-week follow-up study.

Authors:  Tatiana Rafaela Lemos Lima; Leandro Kasuki; Monica Gadelha; Agnaldo José Lopes
Journal:  Endocrine       Date:  2019-07-17       Impact factor: 3.633

Review 5.  Acromegaly in the elderly patients.

Authors:  Maria Rosaria Ambrosio; Irene Gagliardi; Sabrina Chiloiro; Ana Gonçalves Ferreira; Marta Bondanelli; Antonella Giampietro; Antonio Bianchi; Laura De Marinis; Maria Fleseriu; Maria Chiara Zatelli
Journal:  Endocrine       Date:  2020-02-14       Impact factor: 3.633

Review 6.  Multidisciplinary management of acromegaly: A consensus.

Authors:  Andrea Giustina; Garni Barkhoudarian; Albert Beckers; Anat Ben-Shlomo; Nienke Biermasz; Beverly Biller; Cesar Boguszewski; Marek Bolanowski; Jens Bollerslev; Vivien Bonert; Marcello D Bronstein; Michael Buchfelder; Felipe Casanueva; Philippe Chanson; David Clemmons; Maria Fleseriu; Anna Maria Formenti; Pamela Freda; Monica Gadelha; Eliza Geer; Mark Gurnell; Anthony P Heaney; Ken K Y Ho; Adriana G Ioachimescu; Steven Lamberts; Edward Laws; Marco Losa; Pietro Maffei; Adam Mamelak; Moises Mercado; Mark Molitch; Pietro Mortini; Alberto M Pereira; Stephan Petersenn; Kalmon Post; Manuel Puig-Domingo; Roberto Salvatori; Susan L Samson; Ilan Shimon; Christian Strasburger; Brooke Swearingen; Peter Trainer; Mary L Vance; John Wass; Margaret E Wierman; Kevin C J Yuen; Maria Chiara Zatelli; Shlomo Melmed
Journal:  Rev Endocr Metab Disord       Date:  2020-09-10       Impact factor: 6.514

7.  Potential markers of disease behavior in acromegaly and gigantism.

Authors:  Laura C Hernández-Ramírez
Journal:  Expert Rev Endocrinol Metab       Date:  2020-05-06

8.  Characterization of the ability of a, second-generation SST-DA chimeric molecule, TBR-065, to suppress GH secretion from human GH-secreting adenoma cells.

Authors:  Thomas Cuny; Thomas Graillon; Célines Defilles; Rakesh Datta; Shengwen Zhang; Dominique Figarella-Branger; Henry Dufour; Grégory Mougel; Thierry Brue; Tanya Landsman; Heather A Halem; Michael D Culler; Anne Barlier; Alexandru Saveanu
Journal:  Pituitary       Date:  2021-01-12       Impact factor: 4.107

Review 9.  Acromegaly and ultrasound: how, when and why?

Authors:  M Parolin; F Dassie; R Vettor; P Maffei
Journal:  J Endocrinol Invest       Date:  2019-09-09       Impact factor: 4.256

Review 10.  New Horizons: Novel Approaches to Enhance Healthspan Through Targeting Cellular Senescence and Related Aging Mechanisms.

Authors:  Tamar Tchkonia; Allyson K Palmer; James L Kirkland
Journal:  J Clin Endocrinol Metab       Date:  2021-03-08       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.